Results 21 to 30 of about 7,378 (198)
Clinical and Experimental Gastroenterology, 2009 Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative ...
Glen A Doherty, Mark A Peppercorn
doaj +1 more source
Drug Design, Development and Therapy, 2014 David Pierce,1 Mary Corcoran,2 Patrick Martin,2 Karen Barrett,1 Susi Inglis,1 Peter Preston,2 Thomas N Thompson,3 Sandra K Willsie3 1Shire, Basingstoke, UK; 2Shire, Wayne, PA, USA; 3PRA International, Lenexa, KS, USA Background: MMX® mesalamine is a
Pierce D +7 more
doaj +1 more source
Mesalamine-induced myopericarditis - A case report
Revista Española de Enfermedades Digestivas, 2016 Myopericarditis has occasionally been reported as a side effect of mesalamine in patients with inflammatory bowel disease. We present a 20-year-old woman with ulcerative colitis admitted with chest pain. After thorough investigation she was diagnosed with myopericarditis potentially related to mesalamine.
Bernardo,Sónia +2 more
core +5 more sources
Mesalamine-Induced Eosinophilic Pneumonia. [PDF]
CureusEosinophilic pneumonia encompasses a group of lung disorders characterized by peripheral blood eosinophilia. While its etiology is often idiopathic or infectious, non-infectious causes, including drug-induced reactions, should also be considered. Common culprits of drug-induced eosinophilic pneumonia include daptomycin, phenytoin, and nitrofurantoin ...
Sharma M, Sotelo JE, Schultz S.
europepmc +3 more sources
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
Drug Design, Development and Therapy, 2011 Lilliana Oliveira, Russell D CohenThe Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USAAbstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first ...
Lilliana Oliveira, Russell D Cohen
doaj +2 more sources
Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
Patient Preference and Adherence, 2009 Daniel B Zandman, Mark A PeppercornHarvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Mesalamine and its derivatives are effective and well-tolerated therapies for ...
Daniel B Zandman, Mark A Peppercorn
doaj +1 more source
Bridging the Pregnancy Knowledge Gap: A Real-World Analysis of Medication Use and Drug-Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis. [PDF]
Clin Transl SciABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Williams J +4 more
europepmc +2 more sources
Drug-Induced Intersticial Nephritis. Clinical Case
Acta Medica Lituanica, 2021 5-Aminosalicylic acid (5-ASA) preparations are widely used in the treatment of inflammatory bowel diseases. The most commonly used medicine is mesalamine. Overall, it is a very safe drug with few side effects.
Paulina Tekoriutė +2 more
doaj +1 more source
Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. [PDF]
PLoS ONE, 2018 Mesalamine is commonly used to treat ulcerative colitis (UC). Although mesalamine acts topically, in vitro data suggest that intracellular transport is required for its beneficial effect.
Christopher J Moran +5 more
doaj +1 more source
Induction of oxidative DNA damage by mesalamine in the presence of copper: a potential mechanism for mesalamine anticancer activity [PDF]
, 2011 Mesalamine is the first line pharmacologic intervention for patients with ulcerative colitis, and recent epidemiologic studies have demonstrated a protective association between therapeutic use of the drug and colorectal carcinoma. However, the mechanism
Misra, H. P. +20 more
core +2 more sources